Avtor/Urednik		Goričar, Katja; Dugar, Franja; Dolžan, Vita; Marinko, Tanja
Naslov		NBN, RAD51 and XRCC3 polymorphisms as potential predictive biomarkers of adjuvant radiotherapy toxicity in early HER2-positive breast cancer
Tip		članek
Vol. in št.		Letnik 14, št. 18
Leto izdaje		2022
Obseg		str. 1-21
ISSN		2072-6694 - Cancers
Jezik		eng
Abstrakt		: Radiotherapy (RT) for breast cancer significantly impacts patient survival and causes adverse events. Double-strand breaks are the most harmful type of DNA damage associated with RT, which is repaired through homologous recombination (HRR). As genetic variability of DNA repair genes could affect response to RT, we aimed to evaluate the association of polymorphisms in HRR genes with tumor characteristics and the occurrence of RT adverse events in early HER2-positive breast cancer. Our study included 101 breast cancer patients treated with adjuvant RT and trastuzumab. All patients were genotyped for eight single nucleotide polymorphisms in NBN, RAD51 and XRCC3 using competitive allele-specific PCR. Carriers of XRCC3 rs1799794 GG genotype were less likely to have higher tumor differentiation grade (OR = 0.05, 95% CI = 0.01‐0.44, p = 0.007). Carriers of RAD51 rs1801321 TT genotype were more likely to have higher NYHA class in univariable (OR = 10.0; 95% CI = 1.63‐61.33; p = 0.013) and multivariable (OR = 9.27; 95% CI = 1.28‐67.02; p = 0.027) analysis. Carriers of RAD51 rs12593359 GG genotype were less likely to have higher NYHA class in univariable (OR = 0.09; 95% CI = 0.01‐0.79; p = 0.030) and multivariable (OR = 0.07; 95% CI = 0.01‐0.81; p = 0.034) analysis. Carriers of XRCC3 rs1799794 GG genotypes experienced more skin adverse events based on LENTSOMA scale in univariable (OR = 5.83; 95% CI = 1.22‐28.00; p = 0.028) and multivariable (OR = 10.90; 95% CI = 1.61‐73.72; p = 0.014) analysis. In conclusion, XRCC3 and RAD51 polymorphisms might contribute to RT adverse events in early HER2-positive breast cancer patients.
Proste vsebinske oznake		rak dojke radioterapija DNK breast cancer radiotherapy DNA